Medication info
Vforzial Tablet 5/80/10 Milligrams

Vforzial Tablet 5/80/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletValsartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202106224 · Approved 2021.08.27 · Insurance code 694003610

Summary

Main use
Treatment of hypertension and dyslipidemia, and inhibition of arteriosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet of this medicine once daily with water. It is recommended that it be taken at the same time each day, if possible (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the doses of the individual components (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). Do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan must not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout treatment. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. Most patients are controlled with a maintenance dose of 10 milligrams once daily. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and inhibition of arteriosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used in patients who require a combination of Amlodipine and Valsartan, specifically for patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy. Amlodipine dilates blood vessels to lower blood pressure, while Valsartan regulates blood pressure. Additionally, Rosuvastatin improves hypercholesterolemia and dyslipidemia, supporting vascular health and is used as an adjunct when dietary control is insufficient. This medication contributes to delaying the progression of atherosclerosis and reducing the risk of cardiovascular disease, stroke, and myocardial infarction. Therefore, it is used to manage both blood pressure and cholesterol levels together to reduce cardiovascular disease risk.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water. It is recommended that it be taken at the same time each day, if possible (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the doses of the individual components (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). Do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan must not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout treatment. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. Most patients are controlled with a maintenance dose of 10 milligrams once daily. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to a fetus, especially in the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with an allergy to any component of this medication, severely impaired liver or kidney function, or those who are pregnant or breastfeeding should not take this medicine. Patients with low sodium or fluid levels in the body should stabilize their condition before taking this medication, and if hypotensive symptoms appear during treatment, they should lie down and seek medical attention if necessary. Patients with elevated potassium levels or those taking other medications that can increase potassium should have their potassium levels monitored regularly, and patients with impaired kidney function should exercise caution. Particularly, patients who have undergone kidney transplants or have a history of angioedema, or those with severe heart failure or after myocardial infarction should use this medication cautiously and have their blood pressure and kidney function checked frequently. This medication can cause muscle pain, muscle weakness, and in rare cases, severe muscle damage known as rhabdomyolysis, so immediate consultation with a doctor is advised if any unusual muscle symptoms occur. Elderly patients may be more sensitive to this medication, so starting with a lower dose and titrating slowly is advisable. Dizziness or fatigue may occur while driving or operating machinery, so caution is required. This medication may interact with other drugs, so if other medications are currently being taken, it is essential to inform the doctor or pharmacist. Pregnant or breastfeeding women should not take this medication; those planning to become pregnant should consult a doctor. Safety and efficacy in pediatric or adolescent patients has not been established, and its use is not recommended.

Side effects

Peripheral edema, fever, increased ALT, increased AST, increased serum creatinine, flank pain, neck pain, dizziness, sensory impairment, nasopharyngitis, rash, nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, drowsiness, postural dizziness, paresthesia, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, thirst, erythema, sweating, rash, itching, joint swelling, lower back pain, arthritis, muscle cramps, weakness, frequency of urination, polyuria, erectile dysfunction, edema, ankle edema, facial edema, fatigue, flushing, asthenia, facial flushing, diplopia, thrombocytopenia, leukopenia, allergic reactions, hyperglycemia, insomnia, mood changes, tremors, taste disturbances, peripheral neuropathy, hypertonia, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, respiratory distress, rhinitis, vomiting, indigestion, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, dysuria, nocturnal enuresis, serum sickness, increased serum potassium, renal failure, kidney damage, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory infection, viral infection, intestinal vascular edema, diabetes, constipation, pancreatitis, itching, myopathy, rhabdomyolysis, weakness, multiple neuropathy, memory loss, peripheral neuropathy, cough, respiratory distress, thrombocytopenia, jaundice, hepatitis, increased transaminases, eosinophilia, drug reaction with eosinophilia and systemic symptoms (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, headache, chest pain, myalgia, increased CK, constipation, increased AST, weakness, arthralgia, fatigue, numbness, paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is best to store it at room temperature between 1 to 30 degrees Celsius, away from extreme heat or cold conditions.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.